. 2022 Nov 1;26(11):802–809. doi: 10.5152/AnatolJCardiol.2022.1665
Content of this journal is licensed under a Table 1.
Characteristics of Studies and Patients
| Study | NOTION | PARTNER III | EVOLUT | |
|---|---|---|---|---|
| Number of centers | 3 | 71 | 86 | |
| Recruitment period | 2011-2013 | 2012-2016 | 2016-2018 | |
| Valve type | CoreValve, Evolut R, or Evolut PRO | Sapien 3 | CoreValve | |
| Sample size | TAVI | 145 | 496 | 725 |
| SAVR | 135 | 454 | 678 | |
| Male, no. (%) | TAVI | 78 (53.8) | 335 (67.5) | 464 (64.0) |
| SAVR | 71 (52.6) | 323 (71.1) | 449 (66.2) | |
| Mean year | TAVI | 79.2 ± 4.9 | 73.3 ± 5.8 | 74.1 ± 5.8 |
| SAVR | 79 ± 4.7 | 73.6 ± 6.1 | 73.6 ± 5.9 | |
| Mean STS-PROM score | TAVI | 2.9 ± 1.6 | 1.9 ± 0.7 | 1.9 ± 0.7 |
| SAVR | 3.1 ± 1.7 | 1.9 ± 0.6 | 1.9 ± 0.7 | |
| Prior cerebrovascular accident, n (%) | TAVI | 24 (16.6) | 17 (3.4) | 74 (10.2) |
| SAVR | 22 (16.3) | 23 (5.1) | 80 (11.8) | |
| Prior myocardial infarction, n (%) | TAVI | 8 (5.5) | 28 (5.7) | 48 (6.6) |
| SAVR | 6 (4.4) | 26 (5.8) | 33 (4.9) | |
| Peripheral vascular disease, n (%) | TAVI | 6 (4.1) | 34 (6.9) | 54 (7.5) |
| SAVR | 9 (6.7) | 33 (7.3) | 56 (8.3) | |
| Chronic lung disease, n. (%) | TAVI | 17 (11.7) | 25 (5.1) | 104 (15.0) |
| SAVR | 16 (11.9) | 28 (6.2) | 117 (18.0) | |
| Diabetes mellitus, n. (%) | TAVI | 26 (17.9) | 155 (31.2) | 228 (31.4) |
| SAVR | 28 (20.7) | 137 (30.2) | 207 (30.5) | |
| Creatinine level >2 mg/dL, no. (%) | TAVI | 2 (1.4) | 1 (0.2) | 3 (0.4) |
| SAVR | 1 (0.7) | 1 (0.2) | 1 (0.1) |
TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement.